Advances in Protein Characterization
|
|
- Gervase Welch
- 8 years ago
- Views:
Transcription
1 Rapid Assessment of Molecular Similarity between a Candidate Biosimilar and an Innovator Monoclonal Antibody Using Complementary LC MS Methods Intact protein LC MS detected a mass variance of 62 Da and peptide mapping located a difference of two amino acids. Microheterogeneities in glycosylation were confirmed using LC FLR. Waters Corporation Martin Gilar, Hongwei Xie, Asish Chakraborty, Joomi Ahn, Ying Qing Yu, deepalakshmi p. dakshinamoorthy, Weibin Chen, St. John Skilton, Jeffery R. Mazzeo Abstract There is an emerging interest in developing biosimilar monoclonal antibodies (MAbs). To avoid expensive clinical trials and shorten time to market, the biosimilar industry must establish that a developing product is, as much as possible, similar to a marketed innovator product through comprehensive analysis. Here, we demonstrate that ultra high pressure liquid chromatography (UHPLC) and mass spec- Martin Gilar, PhD, is a principal researcher, Hongwei Xie, PhD, is a senior research scientist, Asish Chakraborty, PhD, is a senior chemist, Joomi Ahn is a senior research chemist, Ying Qing Yu, PhD, is a principal chemist, Weibin Chen, PhD, is a principal chemist, St. John Skilton, PhD, is the senior marketing manager, and Jeffery R. Mazzeo, PhD, is the biopharmaceutical business director, all at Waters Corporation, Milford, MA, , martin_gilar@waters.com. Deepalakshmi P. Dakshinamoorthy is a senior applications specialist at Waters India Pvt Ltd, Bangalore, India. 16 Supplement to BioPharm International August
2 trometry (MS) can be used routinely to characterize minor differences between a candidate biosimilar and an innovator IgG1 MAb. A two amino acid residue variance in the heavy chain sequence was detected by LC MS intact protein mass measurement and located by tryptic peptide mapping with data independent acquisition LC MS. Microheterogeneities due to N-linked glycosylation and chemical degradation were comprehensively catalogued and compared. The results show that complementary LC MS methods can be used as a set of routine tools for rapid comparison of molecular similarity between a candidate biosimilar and a commercially available MAb. Recombinant monoclonal antibodies (MAbs) represent a class of efficient, but expensive, biotherapeutics. Developing less costly generic biosimilar MAbs is of great interest to both drug companies and consumers. Biosimilar drugs can be defined as compounds that are as similar as possible, structurally and functionally, to an innovator drug. The driving force for the interest in biosimilars for generic drug manufacturers is the upcoming patent expiration for marketed products. 1 However, developing biosimilar products is challenging. Currently, there are no registered biosimilars in the US, and only recently has a mechanism for their approval been created. 2 Biosimilar manufacturers will be under pressure to ensure that their products conform as closely as possible to existing products if they wish to avoid repeating expensive clinical trials and thus reach the market faster. Therefore they have a vested interest in comprehensive product analysis at all stages of development and manufacturing. The key criteria for approval of biosimilars include quality, efficacy, and safety. Therefore, the generic biopharmaceuticals industry must try to demonstrate consistency of a biosimilar to the innovator reference product in every aspect. A number of physicochemical and biological tests are required by regulatory authorities for the characterization of MAbs. 3,4 European Union regulations specify that state-of-the art characterization studies should be applied to the similar biological product (Section 5.2) 5 and that physicochemical characterization should include a determination of the primary structure (section 5.2.2) while post-translational modifications (PTMs) such as glycosylation exhibit only minor levels of microheterogeneity. In the work presented here, we demonstrate the application of state-of-the-art liquid chromatography (LC) and mass spectrometry ( MS) to perform a comprehensive comparison of innovator and biosimilar MAbs. LC MS analysis was carried out at the intact protein level, providing the information about molecular weight and glycan heterogeneity. Middledown analysis of the MAb after reduction provided mass information on the antibody light chain and heavy chain separately, whereas the bottom-up approach (analysis of the MAb tryptic digest) allowed us to locate and identify the differences in primary MAb sequence and PTMs. For peptide mapping, we used a novel, data-independent acquisition method that allows for simultaneous collection of both MS and fragment ion data for every peptide in the data set independent of their mass, intensity, and retention time. 6,7 The dataindependent MS acquisition method permits reliable acquisition of both quantitative (peptide MS signal) and qualitative (peptide sequence) data in a single LC MS analysis. A mass shift of ~32 Da was observed for all glycoforms, suggesting a modification of the heavy chain. The goal of this manuscript is to demonstrate the utility of a comprehensive set of advanced UHPLC MS methods and their suitability for comprehensive comparison of innovator products and biosimilar MAb drug candidates, using a biosimilar of trastuzumab as an example. Materials and Methods Separations were performed on an Acquity UHPLC system (Waters Corporation) equipped with tunable ultraviolet (TUV; for peptide mapping) or fluorescence (FLR, for released glycan profiling) detectors. All MS measurements were made on a Synapt HDMS system (Waters). The systems were controlled by MassLynx 4.1 software (Waters); data processing was performed with BiopharmaLynx v. 1.2 (Waters). Simglycan (v. 2.75) (Premier Biosoft International) was used for glycan identification from a MALDI MS MS experiment. The conditions of intact protein analysis and peptide mapping were the same as described in recently published papers. 8,9 The conditions for hydrophilic interaction chromatography-fluorescence (HILIC FLR) analysis were described elsewhere. 10 Results and Discussion Intact Protein LC MS Analysis The intact MS analysis of large proteins such as MAbs requires appropriate preparation but can be performed routinely. The samples must be thoroughly desalted before MS analysis to obtain a Supplement to BioPharm International August
3 Figure 1. Intact MAb MS analysis. Multiply charged spectra were deconvoluted into protein molecular mass and compared using BiopharmaLynx software. Heterogeneity is caused by the MAb s glycoforms. Notice the mass shift of biosimilar drug candidate compared to the reference innovator sample. Figure 2. UHPLC MS analysis of reduced MAb samples. Data were processed by BiopharmaLynx software. A) Light chain of innovator and biosimilar MAb are identical. B) Heavy chain of biosimilar candidate MAb shows consistent mass shift of ~32 Da for all protein glycoforms compared to the reference sample. Glycosylation pattern differences were detected. sufficient signal. In our experience, the best results are obtained with on-line desalting. 11 The reversed-phase desalting column was used in an on-line setup to obtain UHPLC MS data shown in Figure 1. Deconvoluted data for the innovator and biosimilar MAbs are presented as a mirror plots; the glycoform annotation is based on the deconvoluted MS signals. One can clearly observe protein mass heterogeneity resulting from the presence of several main protein glycoforms. Several dominant peaks can be distinguished for each MAb sample; the difference in mass of ~162 Da corresponds most likely to loss of galactose, G, and ~146 to fucose, F, from the N-linked glycan core structure. The molecular weight of the innovator MAb is consistent with its expected primary sequence, i.e., its mass corresponds to the sum of the mass of two G0F, G0F/G1F, two G1F, G1F/ G2F, or two G2F glycans (Figure 1, upper trace). Interestingly, the biosimilar candidate shows different glycoform heterogeneity and all main glycoforms show a mass shift of ~64 Da compared with the innovator drug. This shift is putatively caused by the presence of unknown PTMs or by differences in the primary amino acid sequence. Further investigation of intact protein mass data suggests the presence of minor glycoforms such as G0/G0F in each MAb (a mass difference of 146 Da, due to incomplete occupancy of a fucosylation site on one of the two G0F core glycan structures). In addition, a low-level Man5/Man5 form was detected in both MAbs. Although the intact protein analysis is fast and useful, it is difficult to quantitatively measure the relative glycoform ratios, especially for minor glycoform species (Figure 1). Therefore, we performed a partial reduction of MAb samples, followed by on-line desalting and MS analysis. The deconvoluted masses of light and heavy chains are shown in Figures 2A and 2B, respectively. Whereas the light chains are identical, the 18 Supplement to BioPharm International August
4 heavy chain data for the innovator and biosimilar MAbs show a distinct mass shift for all glycoforms. Analyzing the 50-kDa heavy chain alone allows for better assessment of glycosylation heterogeneity (whereas the information about heterogeneity on the intact MAb molecular level is now lost). Man5, G0, G0F, G1, G1F, G2, and G2F glycoforms were clearly distinguishable in deconvoluted MS spectra (Figure 2B). When comparing the innovator to the biosimilar MAb, the consistent mass shift of ~32 Da is observed for all glycoforms, suggesting a possible modification of the biosimilar MAb candidate heavy chain. This is consistent with the previously detected ~64 Da difference in the intact protein mass (i.e., the combined contribution of two heavy chains). In the next section, we describe a peptide mapping experiment used to pinpoint the origins of the mass shift. Figure 3. UHPLC MS tryptic peptide maps of innovator and biosimilar MAbs presented as total ion chromatograms. Figure 4. UHPLC MS data of peptide maps shown as deisotoped and charge reduced chromatograms (all charge states and isotopes were deconvoluted into singly charged ion stick ). Selected part of chromatogram between 3.5 and 7.5 min shows one unique peptide detected in innovator and biosimilar MAb digests. Application of Peptide Mapping to Locate Sequence Variants Tryptic digests of both samples were analyzed using the data-independent acquisition UHPLC MS approach ( UPLC MS E ). It has been shown that data-independent acquisition LC MS with alternate low and elevated collision energy scanning provides significant benefits in terms of completeness and speed of peptide mapping. 8 In contrast to data-dependent acquisition (DDA) LC MS MS, which requires a list of precursors (targeted DDA) or relies on intensitybiased precursor selection on the fly (often resulting in omission of minor peptides), data-independent acquisition MS allows for sequencing of all peptides above the limit of detection and for accurate quantification by MS signals in a single analysis. Figure 3 shows a mirror plot of UHPLC MS peptide maps of the biosimilar and innovator MAbs generated by BiopharmaLy nx software. The detected tryptic peptide masses were matched against the theoretical values using a published trastuzumab sequence. 12 Although the total ion chromatogram traces do not show Supplement to BioPharm International August
5 Figure 5. Spectra of unique peptides, obtained using data-independent acquisition MS, confirm the primary sequence of HCT35 peptides for innovator antibody. As expected, it is EEMTK. Biosimilar drug candidate sequence of the HCT35 peptide is DELTK, which is a known MAb allotype. Figure 6. LC-FLR profiling of released and 2-AB labeled glycans. Peak assignment was verified by reference standards and by MALDI MS analysis. Relative quantitation values shown are based on fluorescence signal. significant differences between samples (Figure 3), the compare function in the software visualized chromatogram regions for each of the MAbs that differed. Besides differences in glycosylation, the software indicated addit ional differences, made apparent by displaying chargereduced and isotope- deconvoluted MS stick chromatogram plots, as shown in Figure 4. The mirror plot of the selected region of the chromatogram highlights that the innovator and biosimilar MAbs each contain a unique peptide without a corresponding signal in the other sample. The peptide HT35 (heavy chain, tryptic peak T35) with the amino acid sequence EEMTK found in the innovator product was not present in the biosimilar candidate MAb. Instead, a peak with a mass of Da was observed. The calculated difference in mass between this unknown peptide and EEMTK is ~32 Da, which correlates with our previous results for the differences in mass in the heavy chain (~32 Da) and intact MAb (~64 Da). The MS data suggest that the innovator and biosimilar MAbs have a local inconsistency in the primary amino acid sequence located in the HT35 peptide. Because the UHPLC MS data contain fragmentation data for all peptides (including the unknown and unidentified ones) it was possible to investigate the unknown peak in BiopharmaLynx, as well as in the PepSeq programs, with the latter capable of assisting de novo sequencing. This task was simplified by the availability of information about alternative MAb allotypes in the DrugBank. 13,14 An alternative sequence matched the HT35 peptide mass and the fragmentation pattern matched the DELTK sequence, with a differ- 20 Supplement to BioPharm International August
6 ence of two amino acids from the innovator MAb EEMTK peptide. Both sequences were confirmed using data-independent acquisition MS (Figure 5). Analysis of Glycans Intact protein UHPLC MS and peptide mapping provided information about the heterogeneity of MAb glycosylation and indicated that there are differences in the glycosylation patterns of the investigated samples. To gather more detailed and quantitative information about the glycosylation patterns, we performed LC analysis using a hydrophilic i nte r ac t ion c h romatog r aphy (HILIC) column of released glyca ns using f luorescent detection (FLR). Glycans were cleaved from MAbs by PNGase F enzyme, labeled with 2-AB fluorescent dye, and analyzed using an Acquity UHPLC HILIC glycan column. Chromatograms featuring well resolved glycans including isomers of G1 a/b and G1F a/b are shown in Figure 6. The HILIC method quantified differences in the glycan profiles of the innovator and biosimilar MAbs. Whereas G1F was the most abundant glycan structure in the innovator product, G0F was the most abundant in the biosimilar sample. The sensitivity of fluorescent detection permits the relative quantitation of minor glycans. Glycan identity was confirmed by LC MS MS. Conclusions Comprehensive investigation of an innovator MAb (trastuzumab) and a biosimilar candidate MAb with LC MS and LC FLR techn iques reve a le d u ne x p e c te d d ifferences in t heir pr ima r y sequence. Intact protein analysis showed mass differences and heterogeneit y in the glycosylation patterns. To further elucidate whether the differences result from sequence variations or post-translation modifications, a peptide mapping experiment was performed, revealing an unexpected peptide sequence. The UHPLC MS data analysis of the peptides in BiopharmaLynx and PepSeq software, in conjunction with information about possible allotype sequences from DrugBank, allowed the identification of the biosimilar candidate drug sequence in a single UHPLC MS experiment. Clear differences in the levels of glycosylation observed in LC MS experiment of intact and denatured MAbs were confirmed by a n LC F L R exper iment w it h released labeled glycans detected by fluorescence. The proposed set of experiments is robust and suitable for characterization and quality monitoring of biopharmaceutical proteins at all stages of drug development. REFERENCES 1. Hughes B. Gearing up for follow-on biologics. Nat Rev Drug Discov. 2009;8: The Patient Protection and Affordable Care Act, Pub.L , 124 Stat. 119 (Mar 23, 2010). 3. Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-igf-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819: Reichert JM, Beck A, Iyer, H. European Medicines Agency workshop on biosimilar monoclonal antibodies, 2 July 2009, London, UK. MAbs. 2009;1: European Commission. Guideline on Similar Biological Medicinal Products containing Biotechnology-derived proteins as active substance: Quality Issues. Brussels, Belgium; 2006 June. Available from: human/biosimilar/ en.pd. 6. Silva JC, Denny R, Dorschel C, Gorenstein MV, Li GZ, Richardson K, et al. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol Cell Proteomics. 2006;5: The MS data suggest that the innovator and biosimilar MAbs have a local inconsistency in the primary amino acid sequence located in the HT35 peptide. 7. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: A virtue of parallel MS acquisition. Mol Cell Proteomics. 2006;5: Xie H, Gilar M, Gebler JC. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal Chem. 2009;81: Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs. 2010;2: Ahn J, Bones J, Yu YQ, Rudd PM, Gilar M. Separation of 2-aminobenzamide labeled glycans using hydrophilic interaction chromatography columns packed with 1.7 microm sorbent. J. Chromatogr B Analyt Technol Biomed Life Sci. 2009;878: Chakraborty AB, Berger SJ, Gebler JC; Waters Corporation. Biopharmaceutical Applications Notebook: A Focus on Protein Therapeutics. Waters application note 2007; en. 12. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752: DrugBank.ca [web site]. Alberta, Canada: David Wishart, Departments of Computing Science & Biological Sciences, University of Alberta. [cited 2010 July 9]. Available from drugbank.ca/drugs/db Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 2009;1: Supplement to BioPharm International August
Fast and Automatic Mapping of Disulfide Bonds in a Monoclonal Antibody using SYNAPT G2 HDMS and BiopharmaLynx 1.3
Fast and Automatic Mapping of Disulfide Bonds in a Monoclonal Antibody using SYNAPT G2 HDMS and BiopharmaLynx 1.3 Hongwei Xie and Weibin Chen Waters Corporation, Milford, MA, U.S. A P P L I C AT ION B
More informationThermo Scientific PepFinder Software A New Paradigm for Peptide Mapping
Thermo Scientific PepFinder Software A New Paradigm for Peptide Mapping For Conclusive Characterization of Biologics Deep Protein Characterization Is Crucial Pharmaceuticals have historically been small
More informationNUVISAN Pharma Services
NUVISAN Pharma Services CESI MS Now available! 1st CRO in Europe! At the highest levels of quality. LABORATORY SERVICES Equipment update STATE OF THE ART AT NUVISAN CESI MS Now available! 1st CRO in Europe!
More informationMultiQuant Software 2.0 for Targeted Protein / Peptide Quantification
MultiQuant Software 2.0 for Targeted Protein / Peptide Quantification Gold Standard for Quantitative Data Processing Because of the sensitivity, selectivity, speed and throughput at which MRM assays can
More informationAB SCIEX TOF/TOF 4800 PLUS SYSTEM. Cost effective flexibility for your core needs
AB SCIEX TOF/TOF 4800 PLUS SYSTEM Cost effective flexibility for your core needs AB SCIEX TOF/TOF 4800 PLUS SYSTEM It s just what you expect from the industry leader. The AB SCIEX 4800 Plus MALDI TOF/TOF
More informationThe Scheduled MRM Algorithm Enables Intelligent Use of Retention Time During Multiple Reaction Monitoring
The Scheduled MRM Algorithm Enables Intelligent Use of Retention Time During Multiple Reaction Monitoring Delivering up to 2500 MRM Transitions per LC Run Christie Hunter 1, Brigitte Simons 2 1 AB SCIEX,
More informationGuideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)
22 May 2014 EMA/CHMP/BWP/247713/2012 Committee for Medicinal Products for Human Use (CHMP) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationEffects of Intelligent Data Acquisition and Fast Laser Speed on Analysis of Complex Protein Digests
Effects of Intelligent Data Acquisition and Fast Laser Speed on Analysis of Complex Protein Digests AB SCIEX TOF/TOF 5800 System with DynamicExit Algorithm and ProteinPilot Software for Robust Protein
More informationQuantification of Multiple Therapeutic mabs in Serum Using microlc-esi-q-tof Mass Spectrometry
Quantification of Multiple Therapeutic mabs in Serum Using microlc-esi-q-tof Mass Spectrometry Paula Ladwig, David Barnidge, Mindy Kohlhagen, John Mills, Maria Willrich, Melissa R. Snyder and David Murray
More informationIn-Depth Qualitative Analysis of Complex Proteomic Samples Using High Quality MS/MS at Fast Acquisition Rates
In-Depth Qualitative Analysis of Complex Proteomic Samples Using High Quality MS/MS at Fast Acquisition Rates Using the Explore Workflow on the AB SCIEX TripleTOF 5600 System A major challenge in proteomics
More informationBiopharmaceutical Glycosylation Analysis
Biopharmaceutical Glycosylation Analysis Glycosylation Analysis: Product Offering Molecular model of erythropoietin with complex N-linked glycans. Courtesy of M.R Wormald and R.A Dwek, Oxford Glycobioloy
More information泛 用 蛋 白 質 體 學 之 質 譜 儀 資 料 分 析 平 台 的 建 立 與 應 用 Universal Mass Spectrometry Data Analysis Platform for Quantitative and Qualitative Proteomics
泛 用 蛋 白 質 體 學 之 質 譜 儀 資 料 分 析 平 台 的 建 立 與 應 用 Universal Mass Spectrometry Data Analysis Platform for Quantitative and Qualitative Proteomics 2014 Training Course Wei-Hung Chang ( 張 瑋 宏 ) ABRC, Academia
More informationUsing Natural Products Application Solution with UNIFI for the Identification of Chemical Ingredients of Green Tea Extract
Using Natural Products Application Solution with UNIFI for the Identification of Chemical Ingredients of Green Tea Extract Lirui Qiao, 1 Rob Lewis, 2 Alex Hooper, 2 James Morphet, 2 Xiaojie Tan, 1 Kate
More informationTackling the data analysis challenge for characterisation of biotherapeutics
CASSS AT 2015 Berlin March 2015 1 Tackling the data analysis challenge for characterisation of biotherapeutics Carsten P Sönksen, Ph.D., Novo Nordisk Tackling the data analysis challenge 2 Personal background:
More informationA Generic Kit-Based Approach for Quantifying Monoclonal Antibody Drugs Through Direct Digestion of Discovery Study Samples
A Generic Kit-Based Approach for Quantifying Monoclonal Antibody Drugs Through Direct Digestion of Discovery Study Samples Mary Lame, Hua Yang, Sherri Naughton, and Erin Chambers Waters Corporation, Milford,
More informationRetrospective Analysis of a Host Cell Protein Perfect Storm: Identifying Immunogenic Proteins and Fixing the Problem
Retrospective Analysis of a Host Cell Protein Perfect Storm: Identifying Immunogenic Proteins and Fixing the Problem Kevin Van Cott, Associate Professor Dept. of Chemical and Biomolecular Engineering Nebraska
More informationof Biologics Using LC/MS in Compliant Laboratories
Demonstrating Comparability and Consistency of Biologics Using LC/MS in Compliant Laboratories Patrick Boyce Biopharmaceutical Marketing Manager Europe & India Waters 2011 Waters Corporation Overview Challenges
More informationProteinPilot Report for ProteinPilot Software
ProteinPilot Report for ProteinPilot Software Detailed Analysis of Protein Identification / Quantitation Results Automatically Sean L Seymour, Christie Hunter SCIEX, USA Pow erful mass spectrometers like
More informationApplication Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary
Application Note Increasing the activity of monoclonal antibody isoforms by MCSGP Category Matrix Method Keywords Countercurrent chromatography, FPLC Antibodies MCSGP FPLC, Biobetters, MCSGP, countercurrent
More informationStructural Analysis of Labeled N-Glycans from Proteins by LC-MS/MS Separated Using a Novel Mixed-Mode Stationary Phase
Structural Analysis of Labeled N-Glycans from Proteins by LC-MS/MS Separated Using a Novel Mixed-Mode Stationary Phase Udayanath Aich 1, Julian Saba 2, Xiaodong Liu 1, Srinivasa Rao 1, and Chris Pohl 1
More informationIncreasing the Multiplexing of High Resolution Targeted Peptide Quantification Assays
Increasing the Multiplexing of High Resolution Targeted Peptide Quantification Assays Scheduled MRM HR Workflow on the TripleTOF Systems Jenny Albanese, Christie Hunter AB SCIEX, USA Targeted quantitative
More informationHenry Shion, Robert Birdsall, Steve Cubbedge, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS
Development of Integrated Informatics Workflows for the Automated Assessment of Comparability for Antibody Drug Conjugates (ADCs) Using LC-UV and LC-UV/MS Henry Shion, Robert Birdsall, Steve Cubbedge,
More informationMetabolomic Profiling of Accurate Mass LC-MS/MS Data to Identify Unexpected Environmental Pollutants
Metabolomic Profiling of Accurate Mass LC- Data to Identify Unexpected Environmental Pollutants André Schreiber 1, David Cox 1, Nadia Pace 1, Christopher Borton 2 1 AB SCIEX, Concord, ntario, Canada; 2
More informationPesticide Analysis by Mass Spectrometry
Pesticide Analysis by Mass Spectrometry Purpose: The purpose of this assignment is to introduce concepts of mass spectrometry (MS) as they pertain to the qualitative and quantitative analysis of organochlorine
More informationApplication Note # LCMS-81 Introducing New Proteomics Acquisiton Strategies with the compact Towards the Universal Proteomics Acquisition Method
Application Note # LCMS-81 Introducing New Proteomics Acquisiton Strategies with the compact Towards the Universal Proteomics Acquisition Method Introduction During the last decade, the complexity of samples
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationDiscovery of Pesticide Protomers Using Routine Ion Mobility Screening
Michael McCullagh, 1 David Eatough, 1 Vincent Hanot, 2 and Séverine Goscinny 2 1 Waters Corporation, Wilmslow, UK 2 Wetenschappelijk Instituut Volksgezondheid Institut Scientifique de Santé Publique, Brussels,
More informationPeptide Mapping 101: Essential Tools for Effective Development and Characterization. Part 1:Introduction to Peptide Mapping
Thank you for joining us! The Webinar will begin shortly Peptide Mapping 101: Essential Tools for Effective Development and Characterization Part 1:Introduction to Peptide Mapping Stephan M. Koza, Ph.
More informationKMS-Specialist & Customized Biosimilar Service
KMS-Specialist & Customized Biosimilar Service 1. Polyclonal Antibody Development Service KMS offering a variety of Polyclonal Antibody Services to fit your research and production needs. we develop polyclonal
More information1 Genzyme Corp., Framingham, MA, 2 Positive Probability Ltd, Isleham, U.K.
Overview Fast and Quantitative Analysis of Data for Investigating the Heterogeneity of Intact Glycoproteins by ESI-MS Kate Zhang 1, Robert Alecio 2, Stuart Ray 2, John Thomas 1 and Tony Ferrige 2. 1 Genzyme
More informationSimultaneous qualitative and quantitative analysis using the Agilent 6540 Accurate-Mass Q-TOF
Simultaneous qualitative and quantitative analysis using the Agilent 654 Accurate-Mass Q-TOF Technical Overview Authors Pat Perkins Anabel Fandino Lester Taylor Agilent Technologies, Inc. Santa Clara,
More informationWATERS QUANTITATIVE ANALYSIS solutions
More sensitivity. More speed. What more can you ask for in a complete quantitative analysis solution? WATERS QUANTITATIVE ANALYSIS solutions THE CHALLENGE OF QUANTITATIVE ANALYSIS Tandem mass spectrometry,
More informationProteinScape. Innovation with Integrity. Proteomics Data Analysis & Management. Mass Spectrometry
ProteinScape Proteomics Data Analysis & Management Innovation with Integrity Mass Spectrometry ProteinScape a Virtual Environment for Successful Proteomics To overcome the growing complexity of proteomics
More informationMethod Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates
Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates Paula Hong and Kenneth J. Fountain Waters Corporation, 34 Maple St., Milford, MA, USA APPLICATION
More informationDefinition of the Measurand: CRP
A Reference Measurement System for C-reactive Protein David M. Bunk, Ph.D. Chemical Science and Technology Laboratory National Institute of Standards and Technology Definition of the Measurand: Human C-reactive
More informationAccurate Mass Screening Workflows for the Analysis of Novel Psychoactive Substances
Accurate Mass Screening Workflows for the Analysis of Novel Psychoactive Substances TripleTOF 5600 + LC/MS/MS System with MasterView Software Adrian M. Taylor AB Sciex Concord, Ontario (Canada) Overview
More informationSession 1. Course Presentation: Mass spectrometry-based proteomics for molecular and cellular biologists
Program Overview Session 1. Course Presentation: Mass spectrometry-based proteomics for molecular and cellular biologists Session 2. Principles of Mass Spectrometry Session 3. Mass spectrometry based proteomics
More informationLa Protéomique : Etat de l art et perspectives
La Protéomique : Etat de l art et perspectives Odile Schiltz Institut de Pharmacologie et de Biologie Structurale CNRS, Université de Toulouse, Odile.Schiltz@ipbs.fr Protéomique et Spectrométrie de Masse
More informationbiopharmaceuticals Join the sweet revolution in Thermo Scientific Glycan Analysis for Biotherapeutics
Thermo Scientific Glycan Analysis for Biotherapeutics Join the sweet revolution in biopharmaceuticals Intact Glycoproteins Glycopeptides Free Glycans Monosacccharides MEETING THE CHALLENGES of Glycan Characterization
More informationAnalysis of Polyphenols in Fruit Juices Using ACQUITY UPLC H-Class with UV and MS Detection
Analysis of Polyphenols in Fruit Juices Using ACQUITY UPLC H-Class with UV and MS Detection Evelyn Goh, Antonietta Gledhill Waters Pacific, Singapore, Waters Corporation, Manchester, UK A P P L I C AT
More informationRobert Birdsall, Eoin Cosgrave, Henry Shion, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS
Automating the Determination of Drug-to-Antibody Ratio (DAR) of Antibody Drug Conjugates (ADCs) Based on Separation by Hydrophobic Interaction Chromatography (HIC) Robert Birdsall, Eoin Cosgrave, Henry
More informationAiping Lu. Key Laboratory of System Biology Chinese Academic Society APLV@sibs.ac.cn
Aiping Lu Key Laboratory of System Biology Chinese Academic Society APLV@sibs.ac.cn Proteome and Proteomics PROTEin complement expressed by genome Marc Wilkins Electrophoresis. 1995. 16(7):1090-4. proteomics
More informationUnique Software Tools to Enable Quick Screening and Identification of Residues and Contaminants in Food Samples using Accurate Mass LC-MS/MS
Unique Software Tools to Enable Quick Screening and Identification of Residues and Contaminants in Food Samples using Accurate Mass LC-MS/MS Using PeakView Software with the XIC Manager to Get the Answers
More informationApplication Note # LCMS-66 Straightforward N-glycopeptide analysis combining fast ion trap data acquisition with new ProteinScape functionalities
Application Note # LCMS-66 Straightforward N-glycopeptide analysis combining fast ion trap data acquisition with new ProteinScape functionalities Introduction Glycosylation is one of the most common and
More informationQuantitative proteomics background
Proteomics data analysis seminar Quantitative proteomics and transcriptomics of anaerobic and aerobic yeast cultures reveals post transcriptional regulation of key cellular processes de Groot, M., Daran
More informationHRMS in Clinical Research: from Targeted Quantification to Metabolomics
A sponsored whitepaper. HRMS in Clinical Research: from Targeted Quantification to Metabolomics By: Bertrand Rochat Ph. D., Research Project Leader, Faculté de Biologie et de Médecine of the Centre Hospitalier
More informationAnalysis of Free Bromate Ions in Tap Water using an ACQUITY UPLC BEH Amide Column
Analysis of Free Bromate Ions in Tap Water using an ACQUITY UPLC BEH Amide Column Sachiki Shimizu, FUJIFILM Fine Chemicals Co., Ltd., Kanagawa, Japan Kenneth J. Fountain, Kevin Jenkins, and Yoko Tsuda,
More informationMRMPilot Software: Accelerating MRM Assay Development for Targeted Quantitative Proteomics
MRMPilot Software: Accelerating MRM Assay Development for Targeted Quantitative Proteomics With Unique QTRAP and TripleTOF 5600 System Technology Targeted peptide quantification is a rapidly growing application
More informationError Tolerant Searching of Uninterpreted MS/MS Data
Error Tolerant Searching of Uninterpreted MS/MS Data 1 In any search of a large LC-MS/MS dataset 2 There are always a number of spectra which get poor scores, or even no match at all. 3 Sometimes, this
More informationMaster course KEMM03 Principles of Mass Spectrometric Protein Characterization. Exam
Exam Master course KEMM03 Principles of Mass Spectrometric Protein Characterization 2010-10-29 kl 08.15-13.00 Use a new paper for answering each question! Write your name on each paper! Aids: Mini calculator,
More informationMass Spectrometry Signal Calibration for Protein Quantitation
Cambridge Isotope Laboratories, Inc. www.isotope.com Proteomics Mass Spectrometry Signal Calibration for Protein Quantitation Michael J. MacCoss, PhD Associate Professor of Genome Sciences University of
More informationusing ms based proteomics
quantification using ms based proteomics lennart martens Computational Omics and Systems Biology Group Department of Medical Protein Research, VIB Department of Biochemistry, Ghent University Ghent, Belgium
More informationMonoclonal Antibody Fragment Separation and Characterization Using Size Exclusion Chromatography Coupled with Mass Spectrometry
Monoclonal ntibody Fragment Separation and haracterization Using Size Exclusion hromatography oupled with Mass Spectrometry uthors Haiying hen Katherine McLaughlin Sepax Technologies, Inc. 5 Innovation
More informationIntroduction to Proteomics 1.0
Introduction to Proteomics 1.0 CMSP Workshop Tim Griffin Associate Professor, BMBB Faculty Director, CMSP Objectives Why are we here? For participants: Learn basics of MS-based proteomics Learn what s
More informationApplication Note # MT-90 MALDI-TDS: A Coherent MALDI Top-Down-Sequencing Approach Applied to the ABRF-Protein Research Group Study 2008
Bruker Daltonics Application Note # MT-90 MALDI-TDS: A Coherent MALDI Top-Down-Sequencing Approach Applied to the ABRF-Protein Research Group Study 2008 In the ABRF-PRG study 2008 [*] the ability to characterize
More informationASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.
ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis June 17, 2014 Presiding: Dr. Keyang Xu (Genentech) and Dr. Fabio Garofolo
More informationAPI 3200 LC/MS/MS SYSTEM. Performance, productivity and value combined
API 3200 LC/MS/MS SYSTEM Performance, productivity and value combined API 3200 LC/MS/MS SYSTEM Reliability, reproducibility, and confidence in your data. With an unmatched heritage of technological innovation
More informationOutline of MassHunter Software Session
Outline of MassHunter Software Session 1. Overview MassHunter Software Programs 2. From ChemStation to MassHunter (Optional) 3. MassHunter Qual and Quant (?) 4. MassHunter for LC/MS Demo Find by Methods:
More informationTutorial for Proteomics Data Submission. Katalin F. Medzihradszky Robert J. Chalkley UCSF
Tutorial for Proteomics Data Submission Katalin F. Medzihradszky Robert J. Chalkley UCSF Why Have Guidelines? Large-scale proteomics studies create huge amounts of data. It is impossible/impractical to
More informationStep-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry
Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high
More informationDRUG METABOLISM. Drug discovery & development solutions FOR DRUG METABOLISM
DRUG METABLISM Drug discovery & development solutions FR DRUG METABLISM Fast and efficient metabolite identification is critical in today s drug discovery pipeline. The goal is to achieve rapid structural
More informationChapter 14. Modeling Experimental Design for Proteomics. Jan Eriksson and David Fenyö. Abstract. 1. Introduction
Chapter Modeling Experimental Design for Proteomics Jan Eriksson and David Fenyö Abstract The complexity of proteomes makes good experimental design essential for their successful investigation. Here,
More informationMonoclonal Antibody Characterization Achieving Higher Throughput and Productivity
Monoclonal Antibody Characterization Achieving Higher Throughput and Productivity Dionex Solutions to Accelerate Monoclonal Antibody R&D and Characterization The throughput and productivity challenge Increasing
More informationNovel Glycan Column Technology for the LC-MS Analysis of Labeled and Native N-Glycans Released from Proteins and Antibodies
Novel Glycan Column Technology for the LC-MS Analysis of Labeled and Native N-Glycans Released from Proteins and Antibodies Udayanath Aich, 1 Ilze Birznieks, 1 Julian Saba, 2 Xiaodong Liu, 1 Rosa Viner,
More informationLaboration 1. Identifiering av proteiner med Mass Spektrometri. Klinisk Kemisk Diagnostik
Laboration 1 Identifiering av proteiner med Mass Spektrometri Klinisk Kemisk Diagnostik Sven Kjellström 2014 kjellstrom.sven@gmail.com 0702-935060 Laboration 1 Klinisk Kemisk Diagnostik Identifiering av
More informationWaters Core Chromatography Training (2 Days)
2015 Page 2 Waters Core Chromatography Training (2 Days) The learning objective of this two day course is to teach the user core chromatography, system and software fundamentals in an outcomes based approach.
More informationAstraZeneca, Macclesfield, UK; 2 Waters Corporation, Manchester, UK; 3 Waters Corporation, Milford, MA, US INT RO DU C T ION WAT E R S SO LU T IONS
Qualitative and Quantitative Characterization of the Metabolome, Lipidome, and Proteome of Human Hepatocytes Stably Transfected with Cytochrome P450 2E1 Using Data Independent LC/MS Suzanne Geenen, 1 Cristian
More informationGlobal and Discovery Proteomics Lecture Agenda
Global and Discovery Proteomics Christine A. Jelinek, Ph.D. Johns Hopkins University School of Medicine Department of Pharmacology and Molecular Sciences Middle Atlantic Mass Spectrometry Laboratory Global
More informationProteomics in Practice
Reiner Westermeier, Torn Naven Hans-Rudolf Höpker Proteomics in Practice A Guide to Successful Experimental Design 2008 Wiley-VCH Verlag- Weinheim 978-3-527-31941-1 Preface Foreword XI XIII Abbreviations,
More informationVALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY
More informationGUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS.
GUIDELINES FOR THE VALIDATION OF ANALYTICAL METHODS FOR ACTIVE CONSTITUENT, AGRICULTURAL AND VETERINARY CHEMICAL PRODUCTS October 2004 APVMA PO Box E240 KINGSTON 2604 AUSTRALIA http://www.apvma.gov.au
More informationAgilent 6000 Series LC/MS Solutions CONFIDENCE IN QUANTITATIVE AND QUALITATIVE ANALYSIS
Agilent 6000 Series LC/MS Solutions CONFIDENCE IN QUANTITATIVE AND QUALITATIVE ANALYSIS AGILENT 6000 SERIES LC/MS SOLUTIONS UNRIVALED ACHIEVEMENT AT EVERY LEVEL The Agilent 6000 Series of LC/MS instruments
More informationMethods for Protein Analysis
Methods for Protein Analysis 1. Protein Separation Methods The following is a quick review of some common methods used for protein separation: SDS-PAGE (SDS-polyacrylamide gel electrophoresis) separates
More informationIndustry Perspective: Advantages of Open Access and Walkup LC/ MS Supporting Protein Drug Discovery and Development
Industry Perspective: Advantages of Open Access and Walkup LC/ MS Supporting Protein Drug Discovery and Development Dawn Stickle, Agilent Technologies Originally presented by Eric Fang, Novartis Overview
More informationEKSIGENT EKSPERT NANOLC 400. Unmatched flexibility for low flow LC/MS
EKSIGENT EKSPERT NANOLC 4 Unmatched flexibility for low flow LC/MS EKSIGENT EKSPERT NANOLC 4 Focused ekspertise In 23, Eksigent changed the way scientists looked at nanoscale chromatography with the introduction
More informationSimGlycan Software*: A New Predictive Carbohydrate Analysis Tool for MS/MS Data
SimGlycan Software*: A New Predictive Carbohydrate Analysis Tool for MS/MS Data Automated Data Interpretation for Glycan Characterization Jenny Albanese 1, Matthias Glueckmann 2 and Christof Lenz 2 1 AB
More informationIntroduction to Proteomics
Introduction to Proteomics Åsa Wheelock, Ph.D. Division of Respiratory Medicine & Karolinska Biomics Center asa.wheelock@ki.se In: Systems Biology and the Omics Cascade, Karolinska Institutet, June 9-13,
More informationChallenges in Computational Analysis of Mass Spectrometry Data for Proteomics
Ma B. Challenges in computational analysis of mass spectrometry data for proteomics. SCIENCE AND TECHNOLOGY 25(1): 1 Jan. 2010 JOURNAL OF COMPUTER Challenges in Computational Analysis of Mass Spectrometry
More informationInvestigating Biological Variation of Liver Enzymes in Human Hepatocytes
Investigating Biological Variation of Liver Enzymes in Human Hepatocytes MS/MS ALL with SWATH Acquisition on the TripleTOF Systems Xu Wang 1, Hui Zhang 2, Christie Hunter 1 1 AB SCIEX, USA, 2 Pfizer, USA
More informationLC/MS Analysis of the Monoclonal Antibody Rituximab Using the Q Exactive Benchtop Orbitrap Mass Spectrometer
LC/MS Analysis of the Monoclonal Antibody Rituximab Using the Q Exactive Benchtop Orbitrap Mass Spectrometer Martin Samonig 1,2, Christian Huber 1,2 and Kai Scheffler 2,3 1 Division of Chemistry and Bioanalytics,
More informationGUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 19 to 23 October 2009 GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) World Health Organization 2009 All rights
More informationGuidance for Industry
Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:
More informationAdvantages of the LTQ Orbitrap for Protein Identification in Complex Digests
Application Note: 386 Advantages of the LTQ Orbitrap for Protein Identification in Complex Digests Rosa Viner, Terry Zhang, Scott Peterman, and Vlad Zabrouskov, Thermo Fisher Scientific, San Jose, CA,
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationMarkerView Software 1.2.1 for Metabolomic and Biomarker Profiling Analysis
MarkerView Software 1.2.1 for Metabolomic and Biomarker Profiling Analysis Overview MarkerView software is a novel program designed for metabolomics applications and biomarker profiling workflows 1. Using
More informationProSightPC 3.0 Quick Start Guide
ProSightPC 3.0 Quick Start Guide The Thermo ProSightPC 3.0 application is the only proteomics software suite that effectively supports high-mass-accuracy MS/MS experiments performed on LTQ FT and LTQ Orbitrap
More informationSimultaneous Qualitative and Quantitative Data Acquisition for Research of Diabetes Drugs
Liquid Chromatography Mass Spectrometry SSI-LCMS-068 Simultaneous Qualitative and Quantitative Data Acquisition for Research of Diabetes Drugs LCMS-8050 Summary By utilizing the LCMS-8050 s ultrafast scan
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q6B. Current Step 4 version
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
More informationLearning Objectives:
Proteomics Methodology for LC-MS/MS Data Analysis Methodology for LC-MS/MS Data Analysis Peptide mass spectrum data of individual protein obtained from LC-MS/MS has to be analyzed for identification of
More informationCatalent Biologics & Clinical Supplies The SMART Solution
Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany
More informationamazon SL Innovation with Integrity Setting New Standards in Performance, Simplicity and Value Ion Trap MS
amazon SL Setting New Standards in Performance, Simplicity and Value Innovation with Integrity Ion Trap Best-In-Class Ion Trap Mass Spectrometer for Routine Analysis The amazon SL entry-level system is
More information# LCMS-35 esquire series. Application of LC/APCI Ion Trap Tandem Mass Spectrometry for the Multiresidue Analysis of Pesticides in Water
Application Notes # LCMS-35 esquire series Application of LC/APCI Ion Trap Tandem Mass Spectrometry for the Multiresidue Analysis of Pesticides in Water An LC-APCI-MS/MS method using an ion trap system
More informationPep-Miner: A Novel Technology for Mass Spectrometry-Based Proteomics
Pep-Miner: A Novel Technology for Mass Spectrometry-Based Proteomics Ilan Beer Haifa Research Lab Dec 10, 2002 Pep-Miner s Location in the Life Sciences World The post-genome era - the age of proteome
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationOverview. Introduction. AB SCIEX MPX -2 High Throughput TripleTOF 4600 LC/MS/MS System
Investigating the use of the AB SCIEX TripleTOF 4600 LC/MS/MS System for High Throughput Screening of Synthetic Cannabinoids/Metabolites in Human Urine AB SCIEX MPX -2 High Throughput TripleTOF 4600 LC/MS/MS
More informationEleanor Riches Waters Corporation, Manchester, UK INTRODUCTION
X E V O T Q MS W IT H AT MOS P H E RIC P R E S SU R E P HOT O IO NIZ AT IO N (A P P I) SOU RC E: T H E IONIZATION OF COMPOUNDS WITH DIVERSE STRUCTURES USING VITAMINS AS A MODEL Eleanor Riches Waters Corporation,
More informationGuidance for Industry
Guidance for Industry Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationAlignment and Preprocessing for Data Analysis
Alignment and Preprocessing for Data Analysis Preprocessing tools for chromatography Basics of alignment GC FID (D) data and issues PCA F Ratios GC MS (D) data and issues PCA F Ratios PARAFAC Piecewise
More informationMAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères 91030 Evry Cedex. www.mabsolut.com. is involved at each stage of your project
Mabsolus-2015-UK:Mise en page 1 03/07/15 14:13 Page1 Services provider Department of MABSolys from conception to validation MAB Solut is involved at each stage of your project Creation of antibodies Production
More information